Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Cytomegalovirus

Cytomegalovirus

5 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Cytomegalovirus

10 trials tracked for Cytomegalovirus: 5 in phase 3 or 4 and 3 with published results. The most-cited published study has 174 citations.

10Trials tracked
5Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 4 1 Phase 3 4 Phase 2 4 Other / NA 1
  1. Phase 4 CMV Antiviral Prevention Strategies in D+R-Liver Transplants ("CAPSIL") Completed · 174 cited
  2. Phase 3 Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040) Completed · 112 cited
  3. Phase 3 MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042) Completed · 4 cited
  4. Phase 3 A Study of Letermovir (MK-8228) to Evaluate Efficacy and Safety for Prevention of Cytomegalovirus Infection in Chinese Hematopoietic Stem Cell Transplant Recipients (MK-8228-045) Completed
  5. Phase 3 Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections Completed
  6. Phase 2 Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant Recipients Completed
Show 4 more trials
  1. Phase 2 Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation Completed
  2. Phase 2 Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults Completed
  3. Phase 2 Valganciclovir Therapy in Infants and Children With Congenital CMV Infection and Hearing Loss Completed
  4. N/A Dried Blood Spot Testing of CMV Detection in HCT Recipients Completed

Showing the 10 most-cited and recently-updated of 10 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Cytomegalovirus: what the trials found

Valganciclovir has been shown to significantly reduce the incidence of Cytomegalovirus (CMV) disease compared to control groups (p=0.0396) 2. However, its use did not result in a statistically significant difference in all-cause mortality (p=0.19) or the incidence of allograft rejection (p=0.60) 2.

Letermovir has demonstrated efficacy in reducing clinically significant CMV infection post-transplant; specifically, 2.8% of patients received Letermovir compared to 18.9% in the control group from week 14 through week 28 (p=0.0005) 3. In other studies, Letermovir was associated with a 32% incidence of clinically significant CMV infection up to week 24 post-transplant 5.

Clinical trials evaluating Valganciclovir in the context of hearing assessments showed no statistically significant differences in hearing outcomes at 6, 12, or 24 months compared to control groups 6. Similarly, a separate study on Valganciclovir for hearing did not find statistically significant differences in improved/unchanged hearing versus worsened hearing at month 6 (p=0.859) or when assessing the best ear specifically (p=0.7068) 8.

Letermovir administration was associated with high rates of adverse events (AEs), reported between 90.9% and 99.2% across different study cohorts, though discontinuation due to AE was low or zero in specific trials [4, 5].

Recent results — preliminary, needs further review

  • mRNA-1647 demonstrated high rates of significant increases (≥2-fold, ≥3-fold, and ≥4-fold) in neutralizing antibodies against both epithelial cell infection and fibroblast infection in both seropositive and seronegative populations 1.

For the clinician treating this condition

  • Valganciclovir is effective in reducing the incidence of CMV disease but does not show a statistically significant impact on all-cause mortality or allograft rejection rates.
  • Letermovir significantly reduces the rate of clinically significant CMV infection post-transplant compared to standard controls.
  • mRNA-1647 induces robust neutralizing antibody responses against both epithelial and fibroblast infections in both seropositive and seronegitive patients.

AI synthesis of 6 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Direct-acting antiviral therapy and diverse viral infections require comprehensive epidemiological and diagnostic strategy review
Infectious Disease Sys. Review
Direct-acting antiviral therapy and diverse viral infections require comprehensive epidemiological and diagnostic strategy review Review Outlines Treatment and Prevention for Various Viral Infections
This systematic review covers the molecular biology, epidemiology, and treatment strategies for various viral infections including Hepatitis…
A comprehensive review outlines the biological traits, diagnosis methods, and treatment strategies for several common viral infections inclu…
Frontiers Sep 19, 2026
TORCH seroprevalence 32.5% in Malaysia; CMV highest, screening urged
Pediatrics Meta-analysis
TORCH seroprevalence 32.5% in Malaysia; CMV highest, screening urged TORCH infections found in 32.5% of Malaysian pregnant women and infants
This meta-analysis of 19 reports estimates a 32.5% overall seroprevalence of TORCH infections among pregnant women and infants in Malaysia, …
A meta-analysis finds 32.5% of pregnant women and infants in Malaysia have been exposed to TORCH infections, with CMV most common.
Aug 24, 2026
HLA alleles and haplotypes influence the magnitude of CMV and EBV specific T-cell responses
Allergy & Immunology Guideline
HLA alleles and haplotypes influence the magnitude of CMV and EBV specific T-cell responses Genetic Markers Linked to T-cell Responses Against CMV and EBV
This guideline synthesizes observational data regarding how HLA class I and II alleles, haplotypes, and HLA-G 3′UTR polymorphisms impact CMV…
Specific genetic markers may influence how the immune system responds to common viruses like CMV and EBV, potentially helping to select bett…
Frontiers Aug 14, 2026
Cytomegalovirus and Long COVID represent convergent failures of host-virus resilience networks and inflammatory circuits
Infectious Disease Sys. Review
Cytomegalovirus and Long COVID represent convergent failures of host-virus resilience networks and inflammatory circuits Cytomegalovirus may play a role in the development of Long COVID
This mini-review explores the intersection of Cytomegalovirus (CMV) biology and Long COVID through a framework of declining organismal resil…
A new theory suggests that a common virus called CMV might drive immune aging and contribute to the symptoms of Long COVID.
Frontiers Aug 7, 2026
Systematic review of artesunate for cytomegalovirus in immunocompromised patients
Infectious Disease Meta-analysis
Systematic review of artesunate for cytomegalovirus in immunocompromised patients A Malaria Drug Shows Promise Against a Common Virus
This systematic review synthesizes evidence from 46 studies regarding artesunate for cytomegalovirus in immunocompromised individuals. The a…
A well-known malaria drug called artesunate may offer a new weapon against a common virus that causes serious harm in people with weakened i…
Frontiers May 7, 2026

Questions about Cytomegalovirus

What are the treatment strategies for Cytomegalovirus compared to other viral infections?

CMV treatment relies on antivirals like valganciclovir, letermovir, and maribavir, plus experimental options such as artesunate, which differs from how many other viruses are treated.

Full answer →
Does the drug artesunate show activity against Cytomegalovirus in immunocompromised patients?

Artesunate kills cytomegalovirus in the lab, including drug-resistant strains, but clinical evidence in immunocompromised patients is limited and mixed, with viral load drops that are not always sustained.

Full answer →